TrialNeurology2025

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Nicola Pietrafusa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.